Therapeutic Area: Neurology Product Name: Albutein
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
Previously presented at various medical congresses, AMBAR findings demonstrate a slowdown in the progression of symptoms in patients with mild-to-moderate Alzheimer's.